Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

Summary

The purpose of this trial is to investigate the safety and tolerability of TAS3681, to find the maximum tolerated dose (MTD)/recommended dose of TAS3681 (Escalation Phase) and to further evaluate safety and preliminary efficacy of TAS3681 at the MTD/recommended dose (Expansion Phase).

Timeline

Start

2016-03

Primary completion

2022-08-09

Completion

2024-04-26

Drugs

Indications